Blog
RSS FeedPosted by Michael Wonder on 22 Jun 2017
Institute for Clinical and Economic Review releases final value assessment framework for 2017-2019
22 June 2017 - Responds to public comment and sets key parameters for evidence review methods and process for stakeholder engagement. ...
Posted by Michael Wonder on 20 Jun 2017
When cholesterol drugs cost $14,000, an insurance tug-of-war
19 June 2017 - Patients struggle to obtain PCSK9 inhibitors, a powerful class of drugs that lower bad cholesterol in difficult ...
Posted by Michael Wonder on 17 Jun 2017
Institute for Clinical and Economic Review report finds inadequate evidence to distinguish between anabolic therapies for osteoporosis
16 June 2017 - Cost-effectiveness analyses find prices too high to align with added benefit to patients. ...
Posted by Michael Wonder on 15 Jun 2017
Institute for Clinical and Economic Review to evaluate voretigene neparvovec in upcoming review
15 June 2017 - First gene therapy to be submitted for approval to FDA; potential for life-time benefits with single ...
Posted by Michael Wonder on 13 Jun 2017
Institute for Clinical and Economic Review’s “new evidence update” on PCKS9 inhibitors highlights lack of mortality benefit with evolocumab
13 June 2017 - Newly released clinical trial data show expected reductions in stroke and heart attack, but mortality benefit ...
Posted by Michael Wonder on 08 Jun 2017
Institute for Clinical and Economic Review's final report on treatments for atopic dermatitis provides policy recommendations to support appropriate patient access to dupilumab
8 June 2017 - Report analyses evidence on the comparative effectiveness of dupilumab, finds price well-aligned with added value for patients; ...
Posted by Michael Wonder on 07 Jun 2017
Converging on the value of value frameworks
6 June 2017 - The relentless increase in health care costs has been difficult to control and is widely believed to ...
Posted by Michael Wonder on 22 May 2017
Another voice: Patients have a right to the treatments ordered by doctors
22 May 2017 - For too long, insurance-backed groups have been given enormous power to overrule doctors’ orders and make ...
Posted by Michael Wonder on 13 May 2017
Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitis
12 May 2017 - Limitations noted on the evidence for crisaborole; analyses find stronger evidence for dupilumab and suggest its price ...
Posted by Michael Wonder on 11 May 2017
Institute for Clinical and Economic Review posts briefing paper on assessing the value of drugs for rare conditions
10 May 2017 - Report contains a technical brief on Spinraza and will inform discussions at ICER pricing summit on 31 ...
Posted by Michael Wonder on 08 May 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for tardive dyskinesia, including recently approved Ingrezza
8 May 2017 - Report expected to review evidence on deutetrabenazine (Austedo), tetrabenazine (Xenazine), and valbenazine (Ingrezza); scoping document will be ...
Posted by Michael Wonder on 07 May 2017
Institute for Clinical and Economic Review's draft evidence report on abuse-deterrent opioids evaluates clinical and economic evidence on nine formulations
5 May 2017 - Public comment period now open until 2 June; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 04 May 2017
ICER releases draft evidence report on treatments for osteoporosis, including abaloparatide and romosozumab
3 May 2017 - Abaloparatide recently approved by FDA, romosozumab under FDA review; public comment and requests to give oral comment ...
Posted by Michael Wonder on 22 Apr 2017
Institute for Clinical and Economic Review to review drugs for tardive dyskinesia in upcoming report
21 April 2017 - Report expected to include review of Ingrezza, recently approved, and Austedo, currently under FDA review; ICER's open ...
Posted by Michael Wonder on 12 Apr 2017
Pharmacy benefit management companies: do they create value in the US health care system?
12 April 2017 - Pharmacy benefit management companies perform functions in the US market-based healthcare system that may be performed by ...